REGENERON PHARMACEUTICALS, INC. financials

  1. Home
  2. Financials
  3. REGN
REGN CIK 0000872589

Source: EDGAR filings · Built 2026-06-02T03:55:35Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 4.08B 3.66B 3.88B 4.42B 6.53B 2.00B
EBITDA 4.12B 4.47B 4.47B 5.08B 9.23B 3.81B
Working Capital 13.65B 14.72B 16.06B 12.74B 10.08B 7.08B
Net Debt -145.40M 450.60M 60.60M -336.30M -185.90M 502.00M
Operating Margin 24.95% 28.10% 30.85% 38.93% 55.67% 42.09%
Net Margin 31.41% 31.07% 30.14% 35.64% 50.25% 41.35%
Return on Equity (ROE) 14.41% 15.03% 15.22% 19.14% 43.03% 31.86%
Return on Assets (ROA) 11.11% 11.69% 11.95% 14.85% 31.75% 20.47%
Current Ratio 4.13× 4.73× 5.69× 5.06× 3.56× 3.63×
Debt-to-Equity 0.10× 0.10× 0.11× 0.12× 0.14× 0.24×
Effective Tax Rate 13.88% 7.68% 5.85% 10.71% 13.41% 7.80%
Cash Conversion Ratio 1.11× 1.00× 1.16× 1.16× 0.88× 0.75×
Accruals Ratio -0.01× -0.00× -0.02× -0.02× 0.04× 0.05×
SBC % of Revenue 6.93% 6.92% 6.75% 5.96% 3.74% 5.08%
CapEx Coverage 5.54× 5.85× 6.39× 8.50× 12.83× 4.26×
Free Cash Flow Per Share $37.57 $31.84 $34.08 $38.98 $58.19 $17.41

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 18.61× 18.58× 25.26× 18.88× 8.77× 15.83×
P/FCF 20.54× 22.37× 25.77× 18.51× 10.85× 27.75×
FCF Yield 4.87% 4.47% 3.88% 5.40% 9.21% 3.60%
EV / EBITDA 20.30× 18.43× 22.36× 16.05× 7.65× 14.72×
P/S 5.84× 5.77× 7.61× 6.73× 4.41× 6.54×
P/B 2.68× 2.79× 3.84× 3.61× 3.78× 5.04×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 14.34B 14.20B 13.12B 12.17B 16.07B 8.50B
Research and Development Expense 5.85B 5.13B 4.44B 3.59B 2.86B 2.65B
Selling, General and Administrative Expense 2.70B 2.95B 2.63B 2.12B 1.82B 1.35B
Operating Income (Loss) 3.58B 3.99B 4.05B 4.74B 8.95B 3.58B
Income Tax Expense (Benefit) 725.80M 367.30M 245.70M 520.40M 1.25B 297.20M
Net Income (Loss) Attributable to Parent 4.50B 4.41B 3.95B 4.34B 8.08B 3.51B
Earnings Per Share, Basic $43.07 $40.90 $37.05 $40.51 $76.40 $32.65
Weighted Average Number of Shares Outstanding, Basic 104.60M 107.90M 106.70M 107.10M 105.70M 107.60M
Earnings Per Share, Diluted $41.48 $38.34 $34.77 $38.22 $71.97 $30.52
Weighted Average Number of Shares Outstanding, Diluted 108.60M 115.10M 113.70M 113.50M 112.20M 115.10M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 3.12B 2.49B 2.73B 3.11B 2.89B 2.19B
Assets, Current 18.02B 18.66B 19.48B 15.88B 14.01B 9.78B
Assets 40.56B 37.76B 33.08B 29.21B 25.43B 17.16B
Liabilities, Current 4.37B 3.94B 3.42B 3.14B 3.93B 2.70B
Long-term Debt, Excluding Current Maturities 1.99B 1.98B 1.98B 1.98B 1.98B 1.98B
Liabilities 9.30B 8.41B 7.11B 6.55B 6.67B 6.14B
Stockholders' Equity Attributable to Parent 31.26B 29.35B 25.97B 22.66B 18.77B 11.03B

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 4.98B 4.42B 4.59B 5.01B 7.08B 2.62B
Net Cash Provided by (Used in) Investing Activities -629.10M -2.47B -3.19B -3.78B -5.38B -70.60M
Payments for Repurchase of Common Stock 3.44B 2.60B 2.23B 2.08B 1.65B 5.85B
Payments of Dividends 370.30M 0 0 — — —
Net Cash Provided by (Used in) Financing Activities -3.72B -2.20B -1.79B -1.01B -1.01B -1.97B

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (REGN CIK 0000872589), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

KSS

KOHLS Corp

SPT

SPROUT SOCIAL, INC.

CCBG

Capital City Bank Group, Inc.